Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€60.53

€60.53

-0.020%
-0.01
-0.020%
-
 
17.12.24 / Tradegate WKN: A112H2 / Name: Catalent / Stock / Pharmaceuticals / Mid Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Catalent Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Catalent

sharewise wants to provide you with the best news and tools for Catalent, so we directly link to the best financial data sources.

News

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War: https://www.marketbeat.com/logos/articles/med_20251118143343_down-45-year-to-date-novo-nordisk-ignites-a-price.jpg
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

For investors in Novo Nordisk (NYSE: NVO), 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting

Why Scholar Rock Stock Got Socked on Monday: https://g.foolcdn.com/editorial/images/837605/person-checking-medicine-on-a-shelf-in-a-pharmacy.jpg
Why Scholar Rock Stock Got Socked on Monday

A potential delay in an important submission was the news item driving Scholar Rock's (NASDAQ: SRRK) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more